Monitor the company's progress in clinical trials and regulatory approvals for its LPT-CBD platform, as successful development could significantly impact its valuation. However, the going concern qualification and history of losses suggest high risk, making this a speculative investment.
Executive Summary
Innocan Pharma Corp, a Canadian-Israeli pharmaceutical tech company, is conducting an IPO to raise approximately $17.98 million (up to $20.82 million with over-allotment) by offering up to 3.75 million units, each consisting of one common share and one warrant. The funds will primarily finance research and development of its LPT-CBD injectable platform for human and veterinary applications. The company operates in a pre-clinical stage with a history of significant losses and an accumulated deficit of $36 million as of September 2025, and its financial statements include a going concern qualification.
Key Financial Metrics
Key Facts
- IPO to raise $17.98 million (up to $20.82 million with over-allotment) by offering up to 3.75 million units
- Each unit consists of one common share and one warrant with an exercise price of $6.875
- Funds will primarily finance research and development of LPT-CBD injectable platform for human and veterinary applications
- Company operates in pre-clinical stage with history of significant losses
- Accumulated deficit of $36 million as of September 2025
- Financial statements include going concern qualification
Financial Impact
Raises $17.98 million for R&D of LPT-CBD platform
Risk Factors
- Going concern qualification
- History of significant losses
- Pre-clinical stage with uncertain regulatory approval
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| F-1/A Filing (Primary) | 0001493152-26-015152 |
| Exhibit: ex23-1.htm | 0001493152-26-015152 |
| Document: 0001493152-26-015152-index-headers.html | 0001493152-26-015152 |
| Document: 0001493152-26-015152-index.html | 0001493152-26-015152 |
| Document: 0001493152-26-015152.txt | 0001493152-26-015152 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Apr 3, 2026 29w ago | F-1/A | $4.95 $1.74 | ▲ +64.85% | ▲ +78.32% | $1.29 (+73.94%) |
Mar 16, 2026 32w ago | F-1 | $5.07 $2.40 | ▲ +52.66% | ▲ +62.52% | $1.29 (+74.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers